Chronic THC Did Not Produce Detected Midazolam Cross-Tolerance in a Small Primate Experiment

Illustration of amber sample vials beside a laboratory analytical instrument

Chronic THC changed sensitivity to cannabinoid drugs without significantly changing sensitivity to midazolam or ketamine on the tested primate response-rate measures. Tolerance to THC did not imply general tolerance to sedating drugs.

The relevant comparison involved three monkeys

In the chronic-treatment experiment, rhesus monkeys performed food-maintained and stimulus-shock-termination tasks. Researchers compared dose-response effects before and during a seventy-one-day THC regimen. The paper included additional animals and procedures, but those should not inflate the sample for this particular comparison.

Positive cannabinoid findings accompanied non-cannabinoid nulls

THC sensitivity decreased markedly, and cross-tolerance appeared in selected comparisons with synthetic cannabinoid agonists. Midazolam and ketamine dose-response sensitivity, however, was not significantly modified. These findings help distinguish receptor-related adaptation from a general reduction in responsiveness to any behavior-suppressing drug.

The null was not a combined-use safety result

The experiment assessed challenge-drug effects around a chronic THC history. It did not establish that co-use is safe, measure breathing during clinical sedation or test driving. Nonsignificance in three animals also does not prove exact equivalence or exclude smaller effects.

Use the result at its actual scale

The animals received controlled injected drugs and performed specific learned tasks. Ordinary cannabis products, other benzodiazepines, alcohol and patient populations were not interchangeable with those conditions. The study weighs against assuming universal cross-tolerance from a cannabis history while leaving individual medication response and combined-exposure risks unresolved.

Related analysis: Cannabis Tolerance Claims: Questions to Ask Before Relying on Expert Testimony.

Primary research

Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids. British journal of pharmacology (2011). DOI: 10.1111/j.1476-5381.2010.01116.x.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

What Did Mental Health Professionals Report After a Breathwork Workshop?

Ulrike Lueken and colleagues asked 48 mental health professionals to take part in a high-ventilation breathwork workshop and rate their experience. The participants reported altered states and also gave their judgments about possible therapeutic uses and risks. Those ratings describe the views of the workshop group. They do not measure…

Spread the love

Read Article: What Did Mental Health Professionals Report After a Breathwork Workshop?

What Changed on an Emotional Face Recognition Task After Psilocybin With Support?

In an open-label study, J. B. Stroud and colleagues found that people with treatment-resistant depression recognized facial emotions faster one month after receiving psilocybin with psychological support. Seventeen patients completed the task at baseline and follow-up. Sixteen untreated controls completed it on the same schedule. The researchers reported a group-by-time…

Spread the love

Read Article: What Changed on an Emotional Face Recognition Task After Psilocybin With Support?

What Did a Young-Adult CBD Survey Reveal About How Users Chose a Dose?

A survey of young adults asked how CBD users chose a dose. Their answers show why a product history needs more detail than a report of CBD use.

Spread the love

Read Article: What Did a Young-Adult CBD Survey Reveal About How Users Chose a Dose?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us